8-KRegulation FD

CENTENE CORP 8-K Report, Regulation FD Disclosure (Nov 10, 2025)

Filed November 10, 2025For Securities:CNC

Summary

Centene Corporation (CNC) has issued an 8-K filing on November 10, 2025, to announce its participation in the UBS 2025 Global Healthcare Conference on November 11, 2025. During this conference and subsequent investor discussions, management will provide commentary on the company's financial outlook. Importantly, this outlook remains consistent with the previously issued full-year 2025 guidance. Specifically, Centene reaffirms its full-year 2025 GAAP forecast of a diluted loss per share not exceeding $(12.85). Concurrently, the company reiterates its adjusted diluted EPS forecast for the full year 2025 to be at least $2.00. The filing also clarifies the company's use of non-GAAP financial measures, emphasizing their utility in assessing ongoing operations and performance consistency, while strongly encouraging investors to review their full GAAP financial statements. Centene also includes its standard forward-looking statements disclaimer, outlining various risks and uncertainties that could affect future performance.

Key Highlights

  • 1Centene Corporation (CNC) to participate in the UBS 2025 Global Healthcare Conference on November 11, 2025.
  • 2Management will discuss the company's financial outlook at the conference and in subsequent investor meetings.
  • 3Full-year 2025 GAAP diluted loss per share forecast remains unchanged, not to exceed $(12.85).
  • 4Full-year 2025 adjusted diluted EPS forecast remains unchanged, at least $2.00.
  • 5The company reiterates its commitment to providing non-GAAP financial measures to aid investor understanding of ongoing operations.
  • 6Webcast and replay information for the conference presentation are provided.
  • 7Standard forward-looking statements and risk factor disclaimers are included.

Frequently Asked Questions

The primary purpose of this 8-K filing is to inform investors about Centene Corporation's participation in the UBS 2025 Global Healthcare Conference and to confirm that management will reiterate the company's previously issued full-year 2025 financial guidance during the event and subsequent discussions.

No, Centene has not updated its full-year 2025 financial outlook. The company explicitly states that the financial outlook to be discussed is consistent with its previously issued GAAP forecast of a diluted loss per share not to exceed $(12.85) and an adjusted diluted EPS forecast of at least $2.00.

Investors can access a live audio webcast of Centene's participation in the conference via a link provided in the filing. A replay of the webcast will also be available following the presentation on Centene's website (www.centene.com) in the Investors section.

Centene provides non-GAAP financial measures, such as adjusted diluted EPS, because it believes these figures are helpful for investors to more accurately assess the ongoing nature of the company's operations and measure performance more consistently across periods. They are used internally for evaluating performance, planning, and determining incentive compensation, and the company believes they offer a more meaningful understanding of core performance over time, particularly when excluding items like amortization of acquired intangible assets and acquisition/divestiture related expenses.